Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.

Eli Lilly vs. Celldex: A Decade of Cost Dynamics

__timestampCelldex Therapeutics, Inc.Eli Lilly and Company
Wednesday, January 1, 20141018810004932500000
Thursday, January 1, 201540110005037200000
Friday, January 1, 20161020260005654900000
Sunday, January 1, 2017961710006070200000
Monday, January 1, 2018664490004681700000
Tuesday, January 1, 2019426720004721200000
Wednesday, January 1, 2020425340005483300000
Friday, January 1, 202130680007312800000
Saturday, January 1, 202214000006629800000
Sunday, January 1, 202330080007082200000
Monday, January 1, 20248418299999
Loading chart...

Cracking the code

Cost of Revenue Trends: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. Eli Lilly and Company, a stalwart in the industry, has consistently demonstrated robust cost management. From 2014 to 2023, their cost of revenue has shown a steady increase, peaking at approximately $7.3 billion in 2021, reflecting a 48% rise from 2014. This trend underscores their strategic investments in innovation and production efficiency.

Conversely, Celldex Therapeutics, Inc., a smaller player, presents a contrasting narrative. Their cost of revenue has fluctuated significantly, with a notable peak in 2016, followed by a sharp decline. By 2023, their costs had plummeted by over 97% from their 2014 high, highlighting the volatility and challenges faced by emerging biotech firms.

These trends offer a fascinating glimpse into the financial strategies and market positions of these two distinct entities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025